5/23/2014 Integra Life Sciences at Integra | Medical Device Company - Medical Technologies

http://www.integralife.com/index.aspx?redir=message 1/3
Company Profile
Message from the CEO
Management Team
Board of Directors
Integra Foundation
AdvaMed Code of Ethics
Compliance
Global Code of Conduct
Terms and Conditions
Quality Policy
President and CEO's Message
To our Stockholders:
In 2013, despite challenges and an evolving healthcare environment, Integra made positive
headway in advancing our strategic goals of execution, optimization and accelerating
growth, and ended the year on a positive note. We entered 2014 with greater stability and
a stronger foundation, and are progressing toward becoming a multi-billion dollar, global
medical technology company that makes a difference in peoples lives and is a high-
quality investment for our stockholders.
Peter Arduini
President and CEO
2013 Highlights
We had several noteworthy accomplishments that have better positioned us for future growth. We:
Closed out the FDA Warning Letter at our Plainsboro, New Jersey, manufacturing facility and made significant
improvements to the quality system in our Aasco, Puerto Rico site;
Announced the acquisition of Confluent Surgical, Inc. and its DuraSeal product line (which ultimately closed in
the first quarter of 2014), which is a great strategic fit with our Neurosurgery business;
Successfully raised net proceeds of over $150 million through the completion of a public offering of common stock;
Completed patient enrollment in the clinical study of Integra Dermal Regeneration Template for the treatment of
diabetic foot ulcers;
Improved our overall manufacturing and supply capabilities in regenerative medicine, including increasing product
yields and overall capacity;
Discontinued low-growth, low-margin products to refine our overall portfolio and better focus our resources on
higher-growth products;
Continued our organizational optimization, announcing the closure of additional sites in Burlington, Massachusetts
and Andover, England, and consolidating two of our surgical instrument sites in Germany into one state-of-the-art
facility in Rietheim-Weilheim, Germany;
Launched over 20 new products in the United States and internationally;
Expanded our international sales efforts, including increasing the size of our direct sales force in Europe and filing
over 50 international product registrations;
Increased the benefits from our recently established centralized sourcing group to optimize our purchases globally
and by division, realizing significant annual savings in the purchase of goods and services;
Made substantial progress toward implementing our global enterprise resource management system; and
Strengthened our ability to collaborate and manage projects by developing program management skills of our
colleagues worldwide.
We Continue To Give Back
We continued to support the community and help advance research and education. The Company donated more than
$4 million worth of products toward charitable surgical missions and surgeon education. The Integra Foundation, which
has supported a wide variety of research, fellowship, community and education efforts for over a decade, made grants

English:US Search
Home > About Integra > Message f rom the CEO
5/23/2014 Integra Life Sciences at Integra | Medical Device Company - Medical Technologies
http://www.integralife.com/index.aspx?redir=message 2/3
worth almost $600,000.
Accelerating Growth in 2014
During 2013, our businesses had several transformative accomplishments that have positioned us well to accelerate
growth.
For our Neurosurgery business, our recent acquisition of the DuraSeal product line is a great example of our core
capability to add technology and scale to our existing, broad portfolio of products that offer numerous solutions for
surgeons. The DuraSeal product line completes our offering of dural repair solutions, providing surgeons with products
for both grafting and sealing the dura. We expect this newly acquired product line to add growth and profitability in
2014.
In our Extremities business, we launched the full Titan shoulder system, which includes total, reverse and humeral
plating systems, greatly expanding our shoulder portfolio and offering surgeons additional patient options. This notable
new product launch opens up a significant new market for us, one that offers a healthy growth rate sustained by
increases in reverse and revision procedures. We are optimistic that we can obtain a meaningful position in this $650
million market, and are making major investments in our sales operation and surgeon training to support our entire
shoulder franchise. We are also investing in early stage technology that will further strengthen our shoulder portfolio, in
years to come.
We have made excellent progress in our Diabetic Foot Ulcer (DFU) clinical trial, designed to support the effectiveness
of our dermal regenerative products in diabetic foot ulcers. In December, we announced the completion of the
enrollment in the study. The study will be complete after a 28-week follow-up, and if successful, our product could help
more surgeons and patients achieve closure of these difficult-to-heal wounds. This will also open up a fast-growing,
billion dollar market to Integra.
Throughout the rest of our product areas, we are developing and launching new products, adding sales representatives,
and streamlining our organization to quickly and efficiently respond to our customers. We believe these efforts will drive
profitable top-line growth.
Advancing Our Strategy
In the past year, we remained focused on the three-pronged strategy that we put in place to drive Integra toward our
vision of a multi-billion dollar, medical technology company improving our core execution across the board, optimizing
the Company, and accelerating growth. Now, more than ever, it is extremely important that we continue to plan and
execute around these three areas.
We made substantial investments in our Quality and Global Operations organizations in 2012 and 2013. Those
investments have had a strong, positive impact throughout our organization, and indeed, on the culture of our Company.
Our leadership team has reinvigorated both organizations and placed quality first in all we do throughout the Company.
These investments capital, training, focus and emphasis have resulted in the lifting of our Warning Letter in our
Plainsboro, NJ facility, enhancements to our Puerto Rico facility, and overall changes to our quality systems at all of
our manufacturing facilities.
We have, and are continuing to make, significant investments in product development. We recently announced the
appointment of Dr. Ken Burhop, Ph.D., as Chief Scientific Officer. He is uniquely qualified to help guide the expansion
of our product pipeline. He will, in part, focus on regenerative medicine, an area that distinguishes us from many other
companies in our industry. It is our Companys founding technology and the common thread that runs throughout our
business. The new structure will allow a focused development team, and more resources and capabilities to bring new
products to market.
Our restructuring plans and supply optimization strategies are progressing well, and 2014 promises to be an important
year of change. The ERP implementation that we have invested in over the past few years is poised to go live this year
across our U.S. commercial operations. The implementation of this system will form a significant portion of the
foundation of our commitment to simplify the way we run our business. We also began the transition process in our
manufacturing facilities in Burlington, Massachusetts and Andover, England, and expect to close both sites by the end
of 2014. These closures will mark further progress toward optimizing our infrastructure through streamlining
manufacturing and distribution, centralizing strategic sourcing, and improving our inventory turns.
Ultimately, our colleagues are our most important assets, and we remain committed to their ongoing development. In
order to execute on the important initiatives that I have outlined, we trained a record number of colleagues on leadership
skills and program management. We are building a strong bench of leaders and a return-focused culture at every level
of the Company.
We expect these investments in our people, our operations, and our systems will make us a stronger company, and
will ultimately improve our earnings and cash flow.
Your Board of Directors
5/23/2014 Integra Life Sciences at Integra | Medical Device Company - Medical Technologies
http://www.integralife.com/index.aspx?redir=message 3/3
We are pleased to welcome Barbara Hill, an Operating Partner of Moelis Capital Partners, and Donald Morel, Jr., Ph.D.,
Chief Executive Officer and Chairman of the Board of Directors of West Pharmaceutical Services, Inc., to our Board of
Directors. They bring unique, complementary perspectives to Integras Board.
We are also grateful to Mr. Neal Moszkowski, who retired from the Board in 2013, for his thirteen years of service on
the Board. His contributions to the Company during his tenure on the Board and its Nominating and Corporate
Governance and Compensation Committees were extremely valuable.
Looking Ahead
2014 is a very special year for Integra because it marks our 25th anniversary. Integra began with the vision of our
founder, Dr. Richard Caruso, to use regenerative medicine products to help heal and regenerate tissue. Regenerative
medicine continues to be at the core of our business, representing approximately 23% of our total revenues. We have
come a long way from the early days when we offered just one product, Integra Dermal Regenerative Template, our
artificial skin product. Today, because of the vision, dedication and commitment of our colleagues from around the
world, we now offer thousands of products and help millions of patients each year.
We are looking forward to celebrating this significant milestone, and continuing to build upon our successes and Dr.
Carusos founding vision.
I am privileged to lead a company that has the people, products and vision to become a recognized industry leader and
continues to help millions of patients worldwide. I would like to thank everyone at Integra for their contributions over the
past year, which have been crucial in strengthening our organization. With your continued support, Integras strong
foundation, and our committed team, I look forward to the great things we will accomplish together.
Sincerely,
Peter Arduini
President and Chief Executive Officer

Copyright 2010-2014 Integra Lif eSciences Corporation. All Rights Reserved. | Terms of use | Privacy policy | Site map